Blog Archives

September 20th, 2011

Slow Spots in Transfer of Primary PCI Patients

In recent years great progress has been made in speeding the delivery of primary PCI to STEMI patients, but lingering problems remain, especially involving the transfer of patients from centers without primary PCI capability. A new study published in Circulation helps to identify the precise causes for delays with these patients.

Michael Miedema and colleagues analyzed data from 2034 patients transferred to the Minneapolis Heart Institute from March 2003 to December 2009. Some 30.4% of patients received treatment within 90 minutes and 65.7% within 2 hours.

Of the patients, 64.0% experienced delays at the referral hospital. Other major occasions of delay were at the primary PCI center (15.7% of patients) and during transfer (12.6% of patients). Delays were most frequently caused by lack of transportation (26.4%) and delays in the ED (14.3%). The longest mean delays were caused by diagnostic dilemmas (95.5 minutes) and nondiagnostic initial ECGs (81 minutes).

In their discussion, the researchers point out that “the cause of the delay may be more important than the actual length of delay” and emphasize that “clinical outcomes vary significantly according to the reason for the delay, and that not all delays are STEMI system dependent.” Most cases of cardiogenic shock or cardiac arrest, for instance, are not a result of a delay but more likely are the cause of a delay, they write. In a press release from the AHA, senior study author Timothy Henry points out that higher-risk patients have the worst outcome and that this phenomenon is related to their advanced disease state and may not be related to a delay in treatment.

The authors write that their study supports a goal for total door-to-balloon time of 120 minutes for transferred STEMI patients.

September 19th, 2011

Decision-Making Shortcuts: The Good and the Bad

A patient comes to the ER complaining of 2 hours of substernal chest pain. An electrocardiogram reveals ST-segment elevation in 3 leads. A critical, ad hoc decision is made to call a “STEMI alert,” thereby activating the cath lab team and an interventional cardiologist. As the late Alvan Feinstein, the Yale educator and father of clinical epidemiology, once noted, “Every observant clinician has discovered that certain ‘short-cuts’ or other maneuvers, either of intellect or of action, can increase the efficiency of his work in clinical practice.”

These cognitive shortcuts are also known as heuristics. Understanding how we use them in medicine can help us improve practice. Because heuristics simplify difficult decisions, they help us avoid “analysis paralysis” under conditions of uncertainty that demand speed. In that way, they can improve decision-making effectiveness. But they can also lead to mistakes. Let’s start by exploring the good side.

The Benefits of Heuristics

Psychologist Gerd Gigerenzer uses an analogy, called a “gaze heuristic,” of a baseball player catching a fly ball. To do it successfully, a player simply fixes his gaze on the ball and starts running. If he maintains a constant angle of gaze by adjusting the direction and speed of his running, he will arrive at just the right spot to make the catch. By concentrating only on the angle of gaze, he can ignore the speed, trajectory, and spin of the ball, as well as the wind and many other factors. In effect, less is better. Gigerenzer has identified an “adaptive toolbox” of heuristics that we commonly use to address various types of problems. Here are a few:

The recognition heuristic enables us to use a single cue or a recognizable pattern of cues to quickly form a conclusion or size up a situation. Rapidly analyzing an ECG to diagnose a STEMI is one example. Seeing a pattern emerge from a patient’s historical narrative, leading to a diagnosis of chronic stable angina, is another.

The one-good-reason heuristic involves analyzing a short series of cues, then stopping when we perceive a strong or compelling cue. An initial ECG showing ST-segment elevation is, for example, a strong enough cue to prompt the immediate action of activating the cardiac cath lab. The trick is to start by first analyzing the high-impact cues.

The tallying heuristic allows us to organize cues in deciding among competing options. In the ER, I recently saw a patient with chest pain and a history of gastroesophageal reflux, which she had hoped was the cause of her pain. But she also had a history of bypass surgery and multiple cardiovascular risk factors. After weighing all the factors, we proceeded to the cath lab. She had two critical lesions and received two stents, and her pain resolved. Research shows that simply tallying up unweighted cues is quite effective. You just need to know which ones to consider.

Anchoring and adjusting, a heuristic I discussed in my previous blog post, describes how we assess subjective probabilities starting with an initial (anchor) impression and then adjust the probability estimate by incorporating new information such as a test result. Used properly, this heuristic can turn you into an intuitive Bayesian thinker.

Expert clinicians know how to filter out weak cues and focus on strong cues, as if separating signal from noise. Strong cues may be a key detail from a patient’s medical history, a bead of sweat on the brow of a patient complaining of chest pain, or certain ECG findings. Weak cues may be unreliable markers such as a soft carotid bruit or the lack of an S3 gallop.

The Risks of Heuristics

Like a medical procedure, heuristics can have both risks and benefits. Psychologists Daniel Kahneman and Amos Tversky studied many of the pitfalls of heuristics, such as these:

The base-rate neglect fallacy, explored in my previous post, surfaces when we misuse the anchoring and adjusting heuristic.

Representativeness involves jumping to an erroneous conclusion that is unlikely to be accurate, on the basis of an initial impression. ECG findings of ST-segment elevation due to early repolarization could lead to the erroneous diagnosis of acute MI in a young patient for whom that diagnosis is very unlikely. The medical adage “when you hear hoof beats, consider that it is a horse not a zebra” helps us avoid this trap.

Availability is a pitfall in which judgment is clouded by salient or recent events that happen to be more available and accessible to our working memory and intuition. Missing an uncommon diagnosis such as aortic dissection can be very troubling and memorable, but we should not then give this possible diagnosis undue weight in assessing subsequent patients.

By guarding against these tendencies, we can improve the chances that our heuristics — which, after all, are often useful — will yield good judgments.

How to Increase Awareness of Heuristics

Most physicians, whether trainees or seasoned clinicians, do not think consciously about heuristics. Becoming more aware of them and developing a common vocabulary will help us use them more effectively. There are two key domains where this kind of change could have a big impact.

Medical Training

Clinicians can be made more conscious of heuristics starting in medical school and continuing during fellowship training. Trainees may subconsciously learn about heuristics through experience, but that method is slow and unreliable. We should be able to teach these simple thinking processes overtly, just as we explicitly teach a one-hand tie to a surgical trainee. On my teaching rounds, I often include a brief discussion of how we use heuristics in medical practice. For example, I talk about anchoring and adjusting to teach the proper use of stress testing. I also discuss the recognition heuristic to illustrate the value of taking a detailed narrative history from a patient — patient-reported cues emerge as a recognizable pattern, like stars in a constellation. Including more explicit training on the use of heuristics would undoubtedly improve the consistency and quality of medical decision making.

Research into Medical Decision Making

Cognitive psychologists may discover other heuristics, but medical research is unlikely to invent new ones. After all, humans evolved to use heuristics long before modern medicine existed. Nonetheless, the cues that heuristics employ are domain-specific, with particular ones in each medical specialty and subspecialty. Analyzing the validity of those commonly used cues may be one way to advance research about decision making in the field of medicine. Addressing the basic science of medical decision making will require new ideas and true creativity.

What are your ideas for how to improve the use of heuristics in the practice of medicine?

September 19th, 2011

“Doc, I Got My Whole Genome Scanned – Now What?”

When Walmart announced that it would stock personal genetic kits, the FDA balked and Walmart held off. But that doesn’t mean patients can’t still order a personal whole genome scan online.

So what do you do if and when your patient shows you a commercially produced report of a personal whole genome scan? Do you treat the results as part of the medical record and manage accordingly? Or do you cite recently reported quality control problems and lack of formal FDA regulation? Or do you refer the patient to a genetic counselor?

With this week’s issue of Nature reporting another 16 new loci for hypertension, the list of genotypes associated with a multitude of phenotypes – from height to Alzheimer’s disease – continues to burgeon. Even though genetic risk scores only modestly predict common complex diseases (e.g. median C statistics of 0.55-0.60 for coronary heart disease), this fact is often lost on the lay media and, in turn, the average public consumer.

So if your next patient showed up in clinic with a genome scan report in hand, what would be your approach?

September 15th, 2011

Xanthelasmata Identified as Independent CV Risk Factor

In a large new study from Denmark, xanthelasmata (raised yellow patches around the eyelids) but not arcus cornae (white or grey rings around the cornea) was found to be an independent risk factor for cardiovascular disease.

In an article in BMJ, Mette Christoffersen and colleagues report on 12,745 adults in Copenhagen without cardiovascular disease at baseline who were followed for a mean of 22 years. At baseline, 4.4% had xanthelasmata and 24.8% had arcus corneae. Here are the main results, comparing the group without xanthelasmata to the group with xanthelasmata:

  • MI: 65 events versus 121 events  per 10,000 person-years (multifactorial-adjusted HR for xanthelasmata, 1.48; 95% CI, 1.23-1.79).
  • Ischemic heart disease: 134 versus 226 events per 10,000 person-years (multifactorial-adjusted HR for xanthelasmata, 1.39; 95% CI, 1.20-1.60)
  • Ischemic stroke: 53 versus 64 events per 10,000 person-years (multifactorial-adjusted HR for xanthelasmata, 0.94; 95% CI, 0.73-1.21)
  • Ischemic cerebrovascular disease: 65 versus 74 events per 10,000 person-years (multifactorial-adjusted HR for xanthelasmata, 0.91; 95% CI, 0.72-1.15)
  • Total deaths: 293 versus 414 events per 10,000 person-years (multifactorial-adjusted HR for xanthelasmata, 1.14; 95% CI, 1.04-1.26)

The authors write that their results “suggest that xanthelasmata are a cutaneous marker of atherosclerosis independent of lipid concentrations and thus should be considered in clinical practice as an independent and additional risk factor for myocardial infarction and ischaemic heart disease.” They say the findings may be especially useful in places with limited access to laboratories.

In an accompanying editorial, Antonio Fernandez and Paul Thompson write that people with xanthelasmata “may have an enhanced biological propensity to deposition of cholesterol in vascular and soft tissue, which is not fully represented by their fasting lipid profiles. Because xanthelasmata are composed of foam cells similar to those present in atherosclerotic plaque, they may be a better marker than arcus corneae of the intra-arterial atherosclerotic process.” Therefore, they conclude, these patients “may therefore require more aggressive management of risk factors.”

September 14th, 2011

Meta-Analysis Finds Reduction in Stent Thrombosis with Everolimus-Eluting Stents

Stent thrombosis and other complications are less likely to occur when everolimus-eluting stents (EES) are used, according to a large meta-analysis appearing in the Journal of the American College of Cardiology.

Usman Baber and colleagues analyzed data from 13 trials that included 17,101 patients who were randomized to either EES or non-EES. They found significant reductions in stent thrombosis, MI, and target vessel revascularization with EES, but did not find a significant difference in cardiac mortality:

  • Stent thrombosis: 0.7% for EES versus 1.5% for non-EES, RR 0.55, CI 0.38-0.78, p=0.001
  • MI: 2.9% versus 3.9%, RR 0.78, CI 0.64-0.96; p=0.02
  • Target vessel revascularization: 5.7% versus 7.7%, RR 0.77, CI 0.64-0.92, p=0.004
  • Cardiac mortality: 1.6% versus 1.9%, RR 0.92, CI 0.74-1.16, p=0.38

The authors state that their data “are the most comprehensive to date evaluating the comparative efficacy and safety of this novel second-generation DES to those of non-EES.” They point out that “any of the EES system components (metallic stent material, strut thickness, polymer, drug, elution properties, healing), or their combination could account for” the better performance of EES in their study.

September 14th, 2011

Study Sheds Light on Consequences of Bicuspid Aortic Valve

Although bicuspid aortic valve (BAV) is the most frequently occurring congenital heart defect, little is known about the long-term prognosis of people with BAV. Now a study published in JAMA shows that although affected people have a low overall rate of aortic complications, their risk is nevertheless about 8 times greater than the risk of those without BAV.

Hector Michelena and colleagues retrospectively followed 416 BAV patients for 16 years. During that period, two patients had an aortic dissection, representing an incidence of 3.1 cases per 10,000 patient-years — more than 8 times the risk of the general population. Risk was higher in people 50 years of age or older (17.4  cases per 10,000 patient-years) and in people with aortic aneurysms at baseline (44.9 cases per 10,000 patient-years).

At baseline, 384 patients did not have an aneurysm. Some 49 went on to develop an aneurysm, representing an incidence of 84.9 cases per 10,000 patient-years — 86 times the risk of the general population. Overall, the 25-year rate of aortic surgery was 25%, and the rate of valve replacement was 53%.

The authors write that their findings “support current recommendations of electively repairing ascending aortic aneurysms and have implications for clinical and echocardiographic surveillance of … patient subsets.”

September 13th, 2011

Is Most Research Done Today a Waste?

Richard Smith (@Richard56), the former editor of BMJ, sent out a tweet earlier today that is worth some reflection. Here it is:

85% of clinical research is waste because the question is unimportant, the design is not right, nothing is published, or the paper is biased

What do you think? Is most research done today a waste? Are researchers really providing knowledge that is valid and useful?

 

 

September 13th, 2011

Follow the Fellows: A Series from the Front Lines

, , and

John RyanFellowship is such a unique experience that we at CardioExchange have wished for it to be documented from the front lines. And so we are introducing a new series, “Follow the Fellows.” We have invited fellows from various fellowship programs around the U.S. to document their course through their training over the next three years.

Our fellows include:

They will be providing periodic updates and commentary on how their training has progressed and how it has influenced them, starting from the earliest days and extending into their final year. We anticipate that this will be a great forum to document modern cardiology training and all the emotions that accompany the various stages — the anxiety on the first night on call, the satisfaction of grasping the minutia of ECG interpretation, the excitement as training finally comes to an end. We encourage our readers to contact us if you would like particular features of training, whether the practical or the emotive aspects, to be addressed.

In this first series of posts, we asked the fellows to share their thoughts regarding their experiences in these first few weeks of fellowship. — John Ryan, Co-moderator, Fellowship Training blog

 

Bill CornwellBill Cornwell — Fellowship has been everything that I anticipated — but all the while something I could only partly prepare for. Dissecting it further is difficult, but anyone who has been there likely knows what I mean. A steep learning curve was expected; after all, on some level I have been through this before. As a student, I marveled at the knowledge my supervising residents had accrued, and as a resident myself, I questioned whether I would ever measure up to the attending physicians who were so accomplished and well versed. Now as a fellow, I am in the shadows of giants in the world of cardiology and again, bewildered by their mastery of the subject, wonder whether I will ever be where they are.

 

Aaron EarlesAaron Earles — I will never forget how anxious I was the night before I began my fellowship. The facility where I completed my internal medicine residency did not have an associated cardiology fellowship, so I did not have access to a fellow to ask advice for what to expect. Another added stressor for me was moving from a rural community to Chicago, where I knew no one. Doubt began to dominate my every thought, to the point where I questioned whether or not I made the appropriate decision to continue training.

 

Kate LindleyKate Lindley — As with each major transition point in my life, I found the first few days of my cardiology fellowship to be full of anxiety, uncertainty, and, well, even fear. As excited as I was to finally begin my career as a cardiologist, I had been out of “the trenches” for a year while serving as an Internal Medicine Chief Resident. As a resident, I was proud of my ability to be extremely efficient without losing an eye for detail. My first day of fellowship, I forgot to check the I/Os on the heart failure patient. I missed a Wenckebach on another patient’s telemetry. The wheel needed some grease.

Day # 2: Saturday call. The echo requests came rolling in. The CT Surgery attending is asking me to evaluate whether an effusion would be better approached percutaneously or surgically. Are you kidding me?! My subcostal echo windows revealed a surgically absent gallbladder. Could I evaluate a patient in the ER for a cardiac etiology of her 50/30 blood pressure? Also, she weighs 350 pounds and has altered mental status. This last case led to a stat “I’m going to need you” consult to the senior fellow.

 

Erica SpatzErica Spatz — Somehow mothers have the uncanny ability to expose the central conflicts that lie within us. I was reminded of this when my own mother, in her struggle to grasp the world of medical training, asked, ‘How are you, a new cardiology fellow, an expert consultant to others?’ How dare she ask this question!

Ummm…. but wait. Does she have a point? During the day we are a team; the fellow is an extension of an expert attending. But at night, when on call, we are on our own. Unfortunately, the night does not respect the inexperience of a first year cardiology fellow — an equivocal STEMI in the ED, a post-ablation with dropping blood pressures, persistent V-tach in a man with prolonged QT…sound familiar?

On call, we are forced to meet our insecurities of being first-year fellows…warriors of the night, if you will. Yet strangely, often the only hints of battle are cries of …

  • outrage!@#, as in this was the most bogus consult; they didn’t even have a clinical question or an electrocardiogram
  • bravado, as in I did a stat echo, gave adenosine, or activated the cath lab
  • relief, as in handing over the call pager.

September 13th, 2011

HHS Announces Initiative to Prevent One Million Heart Attacks and Strokes

The U.S. Department of Health and Human Services is launching a campaign to prevent one million heart attacks and strokes in the next 5 years. The announcement was published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) and in a perspective published in the New England Journal of Medicine by Thomas Frieden, director of the CDC, and Donald Berwick, administrator of the Centers for Medicare and Medicaid Services.

In an analysis of NHANES data, nearly half (49.7%) of U.S. adults in 2007-2008 had at least one of the three main risk factors for CV disease: uncontrolled hypertension, uncontrolled high levels of LDL cholesterol, and current smoking. This represents a significant decline from the 57.8% prevalence reported in 1999-2000. The decrease, according to the CDC, “might, in part, reflect improved treatment and control of hypertension and high levels of LDL-C and implementation of effective smoking interventions.”

Frieden and Berwick write that “it’s time to take the next big step.” In conjunction with other government and private-sector partners, HHS is launching Million Hearts, described by the CDC as “a multifaceted combination of evidence-based interventions and strategies aimed at preventing 1 million heart attacks and strokes over the next 5 years.” Frieden and Berwick state that the Million Hearts initiative will not require new public spending; instead it “will leverage, focus, and align existing investments.”

CV prevention, they write, takes place in the clinic and the community. In the clinical realm, the new initiative will focus on the “ABCS”:

  • aspirin therapy for people at high risk
  • blood pressure control
  • cholesterol management
  • smoking cessation

In the community, the Million Hearts initiative will “encourage efforts to reduce smoking, improve nutrition, and reduce blood pressure.”

September 12th, 2011

Global Monitor: Early Signs of Possible Problems with ICD Leads, Dabigatran

Reports from Ireland and New Zealand may herald new concerns about Riata defibrillator leads (St. Jude Medical) and dabigatran (Pradaxa).

A poster presented at the European Society of Cardiology meeting last month by researchers at the Royal Victoria Hospital in Belfast found that 15% of 212 patients who received Riata leads had an insulation breach on screening. The researchers reported that 20% of the patients had “clinically significant events.”

Quoted in an article in the Minneapolis Star Tribune, the chief of the Arrhythmia Service at Brigham and Women’s Hospital in Boston, Laurence Epstein, acknowledges the small size of the single-center study but states that “it could ultimately be a big issue… we’re just starting to scratch the tip of the iceberg of what the scope of the problem is.” Although the Riata leads were discontinued last year, more than 227,000 were sold worldwide.

In New Zealand, meanwhile, health authorities are struggling with a surge in bleeding complications following the government’s decision to fund dabigatran (Pradaxa). According to an article in the Star Times, the country’s drug monitoring agency “has received around 50 reports of people experiencing bleeding since the drug was introduced two months ago as a replacement” for warfarin.

The Star Times reports that about 56,000 people in New Zealand take warfarin and that thousands have been switched to dabigatran. The reports quotes an official of the country’s Haematology Society: “We do have concerns about the way it was rolled out. … It was rolled out very rapidly without a lot of forethought and planning. In particular the fact that general practitioners could have widespread access to this drug from day one was a concern to us, when some of them did not know how to use it.”